Overview of Dr. Sawyers
Dr. Charles Sawyers is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Johns Hopkins University School of Medicine and has been in practice 32 years. Dr. Sawyers accepts several types of health insurance, listed below. He is one of 498 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
1275 York Ave
New York, NY 10065Fax+1 646-888-2595
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
- University of California (San Francisco)Residency, Internal Medicine, 1985 - 1988
- Johns Hopkins University School of MedicineClass of 1985
Certifications & Licensure
- CA State Medical License 1986 - Present
- NY State Medical License 2006 - 2025
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Elected Member Institute of Medicine, 2008
- Elected Member The American Society for Clinical Investigation, 1999
- Investigator Howard Hughes Medical Institute
Clinical Trials
- BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate Start of enrollment: 2003 Nov 01
- Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse Start of enrollment: 2003 Aug 01
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate Start of enrollment: 2004 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Uncoupling of Akt and mTOR signaling drives resistance to Akt inhibition in PTEN loss prostate cancers.Ninghui Mao, Young Sun Lee, Nazifa Salsabeel, Zeda Zhang, Dan Li
Science Advances. 2025-02-07 - The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1.Rodrigo Romero, Tinyi Chu, Tania J González Robles, Perianne Smith, Yubin Xie
Nature Cancer. 2024-11-01 - 5 citationsSingle-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies.Samir Zaidi, Jooyoung Park, Joseph M Chan, Martine P Roudier, Jimmy L Zhao
Proceedings of the National Academy of Sciences of the United States of America. 2024-07-09
Journal Articles
- Strategies to Identify and Target Cells of Origin in Prostate CancerCharles Sawyers, MD, Journal of the National Cancer Institute
Authored Content
- Tumor Copy Number Alteration Burden Is a Pan-Cancer Prognostic Factor Associated with Recurrence and DeathSeptember 2018
Press Mentions
- New Insights Show ASCL1's Role in Neuroendocrine Prostate Cancer, an Aggressive and Treatment-Resistant TypeOctober 28th, 2024
- Annual Meeting 2022: Opening Plenary Showcases Cutting-Edge Scientific ProgramMay 3rd, 2022
- With CryoEM, MSK Researchers Obtain Exquisite View of the Androgen Receptor — a Key Protein in Prostate CancerApril 20th, 2022
- Join now to see all
Grant Support
- Understanding Resistance To Next Generation AntiandrogensNational Cancer Institute2012
- Translational Research In Oncology Training ProgramNational Cancer Institute2011
- Akt-Independent Pathways Of Phosphoinositide 3-Kinase Dependent TransformationNational Cancer Institute2007–2011
- Mouse Models For Human Prostate CancerNational Cancer Institute2007–2008
- Molecular Biology In Clinical Oncology WorkshopNational Cancer Institute2005–2007
- Mouse Models For Human Prostate CancerNational Cancer Institute2000–2006
- Phase I Trial Of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-Aag, NSC #330National Center For Research Resources2005
- Phase I Trial Of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-Aag, NSC #330...National Center For Research Resources2004
- Targeted Therapy Of PTEN NULL Prostate CancerNational Cancer Institute2002
- Regulation Of The PTEN Tumor Suppressor Gene In Prostate CancerNational Cancer Institute2002
- Imaging Prostate Cancer Bone MetastasisNational Cancer Institute2000–2002
- Regulation Of The PTEN Gene In Prostate CancerNational Cancer Institute2000–2001
- Stem Cell Genes In Prostate Growth And DifferentiationNational Institute Of Diabetes And Digestive And Kidney Diseases1998–2001
- Role Of C-Able Nuclear Tyrosine Kinase In Normal And Malignant Cell GrowthNational Cancer Institute1995–2000
- Mouse Models For Prostate CancerNational Cancer Institute1999
- P53 In Chronic Myelogenous LeukemiaNational Cancer Institute1990–1994
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
GHI PPO
Great West PPO
Multiplan PHCS PPOMultiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: